Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Immunolight LLC is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This volume of active cases suggests a focused prosecution phase for the company's intellectual property assets. The concentration of work in this technical field requires a consistent approach to examiner interactions and legal arguments to ensure successful outcomes.
The portfolio is distributed across 2 distinct examiners and 2 distinct art units. This distribution indicates that the company is navigating multiple examination environments simultaneously. Each art unit often maintains its own internal guidelines and precedents, requiring the applicant to adapt their strategy to different sets of administrative expectations and technical standards.
MOLOYE, TITILAYO is identified as the busiest examiner for this portfolio, currently handling 1 busiest examiner pending action. Monitoring the specific preferences and past decisions of this examiner is a critical component of the current prosecution strategy for the company. The progress of this specific matter will significantly impact the overall timeline for the portfolio's development.
With 2 distinct examiners involved, the company must ensure that arguments made in one part of the portfolio do not conflict with those made in another. The presence of 2 distinct art units further necessitates a versatile legal approach that can address varying interpretations of patent law within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOLOYE, TITILAYO | 1 | 62.5% | +47.9% |
| KOHUTKA, BROOKE NICOLE | 1 | 37.5% | +92.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18010483 | METHOD OF TREATING DIFFICULT TO ACCESS TUMORS WITH PHOTOACTIVATED CANCER THERAPY | KOHUTKA, BROOKE NICOLE | 5d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18010483 | METHOD OF TREATING DIFFICULT TO ACCESS TUMORS WITH PHOTOACTIVATED CANCER THERAPY | KOHUTKA, BROOKE NICOLE | 5d overdue |
| 18496405 | METHODS, DEVICES, AND COMPOSITIONS FOR MEASURING AND INDUCING CELL-TO-CELL COMMUNICATION, AND THERAPEUTIC USES THEREOF | MOLOYE, TITILAYO | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| 3791 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18496405 | METHODS, DEVICES, AND COMPOSITIONS FOR MEASURING AND INDUCING CELL-TO-CELL COMMUNICATION, AND THERAPEUTIC USES THEREOF | MOLOYE, TITILAYO | 1632 | §102§103§112DP | Non-Final OA | — | Pending | Oct 27, 2023 |
| 18010483 | METHOD OF TREATING DIFFICULT TO ACCESS TUMORS WITH PHOTOACTIVATED CANCER THERAPY | KOHUTKA, BROOKE NICOLE | 3791 | §102§103§112 | Final Rejection | 5d overdue | Pending | Dec 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial